Mirum Pharmaceuticals, Inc. (MIRM)
93.99
+0.66
(+0.71%)
USD |
NASDAQ |
Nov 13, 16:00
94.05
+0.06
(+0.06%)
After-Hours: 19:59
Mirum Pharmaceuticals Enterprise Value : 6.499B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 6.499B |
| November 12, 2026 | 6.456B |
| November 11, 2026 | 6.539B |
| November 10, 2026 | 6.527B |
| November 09, 2026 | 6.446B |
| November 06, 2026 | 6.481B |
| November 05, 2026 | 6.470B |
| November 04, 2026 | 6.693B |
| November 03, 2026 | 6.045B |
| November 02, 2026 | 5.961B |
| October 30, 2026 | 5.913B |
| October 29, 2026 | 6.003B |
| October 28, 2026 | 5.966B |
| October 27, 2026 | 5.949B |
| October 26, 2026 | 5.800B |
| October 23, 2026 | 5.612B |
| October 22, 2026 | 5.789B |
| October 21, 2026 | 5.811B |
| October 20, 2026 | 5.917B |
| October 19, 2026 | 5.733B |
| October 16, 2026 | 5.596B |
| October 15, 2026 | 5.742B |
| October 14, 2026 | 5.584B |
| October 13, 2026 | 5.562B |
| October 12, 2026 | 5.982B |
| Date | Value |
|---|---|
| October 09, 2026 | 5.979B |
| October 08, 2026 | 5.675B |
| October 07, 2026 | 5.628B |
| October 06, 2026 | 5.538B |
| October 05, 2026 | 5.680B |
| October 02, 2026 | 5.778B |
| October 01, 2026 | 5.842B |
| September 30, 2026 | 5.944B |
| September 29, 2026 | 5.993B |
| September 28, 2026 | 6.020B |
| September 25, 2026 | 6.133B |
| September 24, 2026 | 6.111B |
| September 23, 2026 | 6.109B |
| September 22, 2026 | 6.243B |
| September 21, 2026 | 6.282B |
| September 18, 2026 | 6.271B |
| September 17, 2026 | 6.724B |
| September 16, 2026 | 6.630B |
| September 15, 2026 | 6.405B |
| September 14, 2026 | 6.590B |
| September 11, 2026 | 6.685B |
| September 10, 2026 | 6.840B |
| September 09, 2026 | 6.690B |
| September 08, 2026 | 6.770B |
| September 04, 2026 | 6.858B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 20.86B |
| Galectin Therapeutics, Inc. | 328.95M |
| TG Therapeutics, Inc. | 10.00B |
| Ardelyx, Inc. | 746.69M |
| Kodiak Sciences, Inc. | 7.208B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.77M |
| Revenue (Quarterly) | 185.72M |
| Total Expenses (Quarterly) | 226.49M |
| EPS Diluted (Quarterly) | -0.6221 |
| Gross Profit Margin (Quarterly) | 81.01% |
| Profit Margin (Quarterly) | -21.95% |
| Earnings Yield | -16.19% |
| Normalized Earnings Yield | -6.329 |